PFF

Gain Therapeutics Presents New Preclinical Data Demonstrating Potential Disease Modifying Benefits of its Novel Brain Penetrant Small Molecule Candidate GT-02287 in Two Preclinical Models of Parkinson’s Disease

Retrieved on: 
月曜日, 9月 19, 2022
Risk, Conduritol, Neurodegeneration, Safety, COVID-19, Glycogen storage disease, AD, International Congress on Tuberculosis, Research, Association, Company, Senior, MJFF, Industry, Therapy, Mouse, U.S. Securities and Exchange Commission, Dopaminergic, Patient, Movement disorders, Protein, Terminology, Pathology, Nasdaq, GBA1, Frasier, The Michael J. Fox Foundation, Security (finance), GLOBE, Movement, Animal, Growth hacking, PD, Neuron, PFF, Drug discovery, GBA, STAR, CBE, Pharmaceutical industry, Vaccine

BETHESDA, Md., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational drug discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced the presentation of new preclinical data at the International Congress of Parkinson’s Disease and Movement Disorders 2022 Annual Meeting in Madrid, Spain, evaluating the neuroprotective effect of Gain’s lead ‘Structurally Targeted Allosteric Regulator’ (STAR) compound, GT-02287, in preclinical in vitro and in vivo models of Parkinson’s disease.

Key Points: 
  • We are especially excited by these latest data which expand on the accumulating preclinical evidence supporting the potential disease-modifying properties of our novel small molecule candidate, GT-02287, said Joanne Taylor, Ph.D., Senior Vice President of Research at Gain Therapeutics.
  • If these results are supported in future clinical studies, GT-02287 could become an important first-in-class disease-modifying therapy for Parkinsons disease.
  • In the first study, the ability of GT-02287 to neutralize CBE-mediated neurodegeneration was evaluated in rat mesencephalic neurons.
  • Mutations in the GBA1 gene, encoding the lysosomal enzyme GCase, represents the most common genetic risk factor for Parkinsons disease (PD).

Ethos Asset Management Inc., USA Announces Deal with Homeland Conservation Alliance, with a Philanthropic Financing Facility (PFF) Agreement to Finance Programs Aligned with Conserving the Colorado River Basin and Surrounding Areas

Retrieved on: 
水曜日, 8月 24, 2022
Partnership, Corps of Engineers, Colorado River, SAN, AHI, Water quality, Engineer, Corps, PFF, Water supply, Erosion, DEQ, Water, Marine Conservation Alliance, Forestry, Agriculture, Aquaculture, Ethos

SAN DIEGO, Aug. 24, 2022 /PRNewswire/ -- ETHOS ASSET MANAGEMENT INC USA, announced a new long-term financing partnership with Homeland Conservation Alliance. The Colorado River and its tributaries provide water to nearly 40 million people, both inside and outside of the basin, and irrigates nearly 5.5 million acres of agricultural lands. This river system is critical to the ecological quality in North America. Ethos has committed to providing significant capital infusion that will continue for several years.

Key Points: 
  • SAN DIEGO, Aug. 24, 2022 /PRNewswire/ -- ETHOS ASSET MANAGEMENT INC USA , announced a newlong-term financing partnership with Homeland Conservation Alliance.
  • "We're absolutely delighted to partner with Homeland Conservation Alliance for such an important and critical environmental project under our Philanthropic Financing Facility (PFF).
  • We thank Kristen Stocks, Project Consultant for Homeland Conservation Alliance, for her support to Ethos and Homeland Conservation Alliance for making the onboarding and evaluation process simple and efficient.
  • Homeland Conservation Alliance was started in 2021 and is comprised of a group of like-minded, environmentally conscious individuals.

Second Annual ILD Day to Drive Awareness of Interstitial Lung Disease on Sept. 14

Retrieved on: 
水曜日, 8月 24, 2022
Inflammation, CDT, BBB, Scar, Fatigue, Rheumatoid arthritis, Research, Caregiver, CEO, Pulmonary fibrosis, Awareness, Disease, Scleroderma Research Foundation, PFF, Sarcoidosis, Scleroderma, Interstitial lung disease, Organization, Foundation, National Health Council, DM, PF, Patient, Better Business Bureau, Myositis, Certification, Dermatomyositis, IPF, Oxygen, Cystic Fibrosis Foundation, Cough, Polymyositis, Charity Navigator, Idiopathic pulmonary fibrosis, Medical device, Medicine, ILD

CHICAGO, Aug. 24, 2022 /PRNewswire/ -- Nine organizations are joining forces to present the second annual ILD Day on Wednesday, Sept. 14, to drive awareness of interstitial lung disease (ILD).

Key Points: 
  • CHICAGO, Aug. 24, 2022 /PRNewswire/ -- Nine organizations are joining forces to present the second annual ILD Day on Wednesday, Sept. 14, to drive awareness of interstitial lung disease (ILD).
  • PF can be seen in many types of ILD and the damage caused by ILD can be irreversible and worsen over time.
  • "The goal of ILD Day is to expand the understanding of ILD among patients and healthcare providers, and to share resources and support for those who are living with the disease."
  • ILD Day was created to drive awareness of interstitial lung disease (ILD) in 2021 and is recognized annually on the second Wednesday in September.

Pulmonary Fibrosis Care Expands To 74 Medical Centers In U.S.

Retrieved on: 
水曜日, 8月 10, 2022
Quality, Respiratory disease, MSN, Hospital, Medical college, NP, ILD, Cystic Fibrosis Foundation, PF, RN, Research, Caregiver, PFF, Radiology, Patient, CCN, Rush University Medical Center, Interstitial lung disease, Doctor of Philosophy, Pulmonary fibrosis, Pathology, Rheumatology, University, Pulmonology, Medicine

CHICAGO, Aug. 10, 2022 /PRNewswire/ -- Americans living with pulmonary fibrosis, a life-threatening lung disease, have gained access to specialized care through the Pulmonary Fibrosis Foundation's (PFF) Care Center Network (CCN).

Key Points: 
  • CHICAGO, Aug. 10, 2022 /PRNewswire/ -- Americans living with pulmonary fibrosis, a life-threatening lung disease, have gained access to specialized care through the Pulmonary Fibrosis Foundation's (PFF) Care Center Network (CCN).
  • The Pulmonary Fibrosis Foundation (PFF) has announced that six new sites have joined the CCN to help diagnose, treat, and provide support for the more than 250,000 Americans living with pulmonary fibrosis (PF).
  • "Our new PFF Care Center Network sites offer much-needed comprehensive care for patients living with PF and interstitial lung disease (ILD).
  • The 74 sites now operating in the PFF Care Center Network are:

Bintai Kinden JV Wins Contracts to Supply O&G-Related Equipment

Retrieved on: 
木曜日, 7月 28, 2022
Petro, Knowledge, Industry, Partnership, PFF, Bursa, Contract, M&E, KBK, O&G, Hydraulic machinery

Bintai Kinden, through wholly-owned subsidiary Kejuruteraan Bintai Kindenko Sdn Bhd (KBK), has a 51% interest in Bintai Energy, with the other 49% interest held by PFF.

Key Points: 
  • Bintai Kinden, through wholly-owned subsidiary Kejuruteraan Bintai Kindenko Sdn Bhd (KBK), has a 51% interest in Bintai Energy, with the other 49% interest held by PFF.
  • KBK is a M&E engineering services specialist while PFF is a supplier of pipes, flanges, fittings, valves and other O&G-related equipment.
  • Bintai Energy has been awarded with similar contracts since its establishment in March 2022 and we hope to be able to win more such contracts given our expertise and knowledge."
  • With the most recent sub-contracts, Bintai Energy has clinched a total of approximately RM9.0 million under the Bintai Energy JV since its formation.

ZyVersa Therapeutics and University of Miami Awarded a Grant from The Michael J. Fox Foundation to Determine if Inhibition of Microglial Inflammasome Activation with IC 100 Blocks Neuroinflammation Driving Parkinson's Disease Pathology

Retrieved on: 
水曜日, 7月 27, 2022
Goal, Inflammation, University, View, Phenotype, Multiple sclerosis, Kidney, Awareness, Center, Neurosurgery, Paralysis, ASC, Physiology, Traumatic brain injury, Twitter, Foundation, The Michael J. Fox Foundation, Parkinson's disease, Research, Government, FSGS, PFF, Associate, CNS, NIH Intramural Research Program, Therapy, Focal segmental glomerulosclerosis, Multimedia, DRS, Volunteering, Clinical trial, Fox Trial Finder, Ageing, Inflammasome, Cognitive neuroscience, Kidney disease, Miami, Patient, LinkedIn, Department, Stroke, Faculty, Microbiology, Alport syndrome, Invention, MJFF, Miami Project to Cure Paralysis, Pharmaceutical industry, Medicine, Immunology, Biophysics, Facebook

WESTON, Fla., July 27, 2022 /PRNewswire/ -- ZyVersa Therapeutics, Inc. (ZyVersa), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, is honored to receive a grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to determine if IC 100 inhibition of inflammasomes and ASC specks blocks microglial-mediated inflammation in a PD model. The research will be conducted at the University of Miami Miller School of Medicine in the labs of IC 100 inventors, Drs. Robert W. Keane and Juan Pablo de Rivero Vaccari. Dr. Keane is Professor, Departments of Physiology and Biophysics, Neurological Surgery and Microbiology, Immunology, and The Miami Project to Cure Paralysis at the University of Miami Miller School of Medicine. Dr. de Rivero Vaccari is an Associate Professor in the Department of Neurological Surgery and The Miami Project to Cure Paralysis, and a Distinguished Faculty Member of the Center for Cognitive Neuroscience and Aging at the University of Miami Miller School of Medicine.

Key Points: 
  • Fox Foundation for Parkinson's Research (MJFF) to determine if IC 100 inhibition of inflammasomes and ASC specks blocks microglial-mediated inflammation in a PD model.
  • The research will be conducted at the University of Miami Miller School of Medicine in the labs of IC 100 inventors, Drs.
  • Dr. Keane is Professor, Departments of Physiology and Biophysics, Neurological Surgery and Microbiology, Immunology, and The Miami Project to Cure Paralysis at the University of Miami Miller School of Medicine.
  • Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today.

Pulmonary Fibrosis Foundation Introduces Community Registry for Self-Reported Data

Retrieved on: 
月曜日, 7月 18, 2022
Research, Transplant, Lung, Disease, Atmosphere, Patient, Registry, Database, Hospital, Organic, Interstitial lung disease, Inflammation, Foundation, BBB, Charity Navigator, Technology, MBA, Risk, Pulmonary fibrosis, National Health Council, Cystic Fibrosis Foundation, Survival, Caregiver, Probability, Rockcastle Regional Hospital and Respiratory Care Center, Better Business Bureau, MS, Sex, Boehringer Ingelheim, Speller, PFF, Scar, Health, Hoffmann-La Roche, Community, Anticoagulant, Disorder, Awareness, United Therapeutics, Medical device, ILD, Genentech, MD

CHICAGO, July 18, 2022 /PRNewswire/ -- The Pulmonary Fibrosis Foundation (PFF) has launched the PFF Community Registry, a distinct data set of the PFF Registry™ that will collect participant-reported data provided directly by patients with pulmonary fibrosis (PF) and interstitial lung disease (ILD), their caregivers and family members, and lung transplant recipients previously diagnosed with PF or ILD.

Key Points: 
  • CHICAGO, July 18, 2022 /PRNewswire/ -- The Pulmonary Fibrosis Foundation (PFF) has launched the PFF Community Registry, a distinct data set of the PFF Registry that will collect participant-reported data provided directly by patients with pulmonary fibrosis (PF) and interstitial lung disease (ILD), their caregivers and family members, and lung transplant recipients previously diagnosed with PF or ILD.
  • Pulmonary fibrosis means scarring of the lung and can be seen in many types of ILD.
  • The PFF Community Registry will complement the PFF Patient Registry, established in 2016 to track medical data from more than 2,000 PF patients across PFF Care Centers nationwide.
  • The Pulmonary Fibrosis Foundation mobilizes people and resources to provide access to high quality care and leads research for a cure so people with pulmonary fibrosis will live longer, healthier lives.

PFF Walk Celebrates Hope and Community for People Affected by Pulmonary Fibrosis

Retrieved on: 
火曜日, 7月 12, 2022
Liberty State Park, Registry, Disease, Charity Navigator, Walkers, Prevalence, Pulmonary fibrosis, Education, Awareness, Better Business Bureau, National Health Council, Foundation, PF, Patient, CEO, PFF, City, Liberty, Walking, Degenerative disease, Research, Cystic Fibrosis Foundation, BBB, Caregiver, Interstitial lung disease, Pharmaceutical industry, Engineered wood, Medicine

CHICAGO, July 12, 2022 /PRNewswire/ -- The Pulmonary Fibrosis Foundation's (PFF) sixth annual PFF Walk returns in person and virtually from July through October 2022 to raise funds and awareness to support people living with pulmonary fibrosis (PF).

Key Points: 
  • CHICAGO, July 12, 2022 /PRNewswire/ -- The Pulmonary Fibrosis Foundation's (PFF) sixth annual PFF Walk returns in person and virtually from July through October 2022 to raise funds and awareness to support people living with pulmonary fibrosis (PF).
  • "We have a community of champions who have remained strong through the pandemic while battling this serious lung disease," said William T. Schmidt, PFF President and CEO.
  • The new PFF Community Registry , launching in July, will be featured at a tent at the Walk sites.
  • The mission of the Pulmonary Fibrosis Foundation is to accelerate the development of new treatments and ultimately a cure for pulmonary fibrosis.

Ethos Asset Management Inc., USA Announces Sustainability and Net Zero Bonus to Clients Reducing Interest Rates and Confirms 49 million USD Awarded Under Philanthropic Financing Facility in 2021

Retrieved on: 
木曜日, 7月 7, 2022
Ethos, 2016 United Nations Climate Change Conference, United Nations, Social responsibility, Philanthropy, Paris Agreement, Kyoto Protocol, Carbon, Climate, United Nations Framework Convention on Climate Change, Foundation, Growth, Climate change, PFF, Goal, Global Financing Facility, Organic, Culture, Automation, SAN, ZERO, Carbon accounting, Paris, University, Social Problems, CSS, Organization, Corporate social responsibility, Temperature, Time, Government, Biodiversity, NET, UNFCCC, Renewable energy, Recycling, Agriculture, Bank

Sustainability cannot be established without changing the paradigms of production and the pricing of common properties, both leading to an increase of production costs.

Key Points: 
  • Sustainability cannot be established without changing the paradigms of production and the pricing of common properties, both leading to an increase of production costs.
  • Being aware of its responsibility Ethos Asset Management pledges to contribute to tackle the challenges by promoting projects committed to NET ZERO EMISSIONS PRODUCTION.
  • Within its Financing Facilities, Ethos will grant a 0.5% reduction to interest rates for project financing applications presenting accountability concepts safeguarding the NET ZERO EMISSION target and overall sustainability.
  • Furthermore, ETHOS will preferentially approve financing for projects openly and accountably being committed to sustainable rules of conduct.

I Am Athlete Inks Content Deal with SiriusXM

Retrieved on: 
月曜日, 4月 25, 2022
Newton, NFL, News, Athlete, PFF, WNBA, NASDAQ, IAA, Human, Atmosphere, SVP, Love, Company, LeSean, National Election Pool, Sirius XM, Rookie, Radio, List of Sirius XM Radio channels, Sport, Partnership, House, NBA, SIRI, Toy, Entertainment, HOA

NEW YORK, April 25, 2022 /PRNewswire/ -- SiriusXM and I Am Athlete, the athlete-led media network founded by former NFL All-Pro receiver Brandon Marshall, announced today they have joined forces in a new expansive content deal that includes a live nightly radio show and other game-changing projects.

Key Points: 
  • I Am Athlete and SiriusXM will produce a new nightly show that will air nationwide on SiriusXM's Mad Dog Sports Radio (channel 82 on SiriusXM radios and on the SXM App).
  • I Am Athlete Tonight episodes will also be available as podcasts after they air on SiriusXM.
  • SiriusXM is an extraordinary company that shares our passion for innovation in storytelling and giving the athlete a platform," said Marshall.
  • And together, we look forward to developing new talent and content for I Am Athlete and SiriusXM that will appeal to listeners everywhere."